miR-199a-3p downregulation in thyroid tissues is associated with invasion and metastasis of papillary thyroid carcinoma

References

• Hundahl SA, Fleming ID, Fremgen AM, et al. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. Cancer. 1998;83:2638–2648.10.1002/(ISSN)1097-0142
   PubMed Web of Science ®Google Scholar
• Oyer SL, Smith VA, Lentsch EJ. Reevaluating the prognostic significance of age in differentiated thyroid cancer. Otolaryngol Head Neck Surg. 2012;147:221–226.10.1177/0194599812441587
   PubMed Web of Science ®Google Scholar
• Kim KM, Park JB, Bae KS, et al. Analysis of prognostic factors in patients with multiple recurrences of papillary thyroid carcinoma. Surg Oncol. 2012;21:185–190.10.1016/j.suronc.2011.07.004
   PubMed Web of Science ®Google Scholar
• Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–1057.
   PubMed Web of Science ®Google Scholar
• Jeon HM, Lim BJ, Chang HS, et al. The definition of minimal extrathyroid extension in thyroid pathology by analyzing sizable intra- and extrathyroid blood vessels. Korean J Pathol. 2012;46:548–553.10.4132/KoreanJPathol.2012.46.6.548
   PubMedGoogle Scholar
• Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10:389–402.10.1038/nrc2867
   PubMed Web of Science ®Google Scholar
• Di Leva G, Croce CM. Roles of small RNAs in tumor formation. Trends Mol Med. 2010;16:257–267.10.1016/j.molmed.2010.04.001
   PubMed Web of Science ®Google Scholar
• Yip L, Kelly L, Shuai Y, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18:2035–2041.10.1245/s10434-011-1733-0
   PubMed Web of Science ®Google Scholar
• Menon MP, Khan A. Micro-RNAs in thyroid neoplasms: molecular, diagnostic and therapeutic implications. J Clin Pathol. 2009;62:978–985.10.1136/jcp.2008.063909
   PubMed Web of Science ®Google Scholar
• Gu S, Chan WY. Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Med. 2012;13:8449–8466.
   Google Scholar
• Kinose Y, Sawada K, Nakamura K, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. 2015;6:11342–11356.
   Google Scholar
• Shen Q, Cicinnati VR, Zhang X, et al. Role of microRNA-199a-5p and discoidin domain receptor 1 in human hepatocellular carcinoma invasion. Mol Cancer. 2010;9:227.10.1186/1476-4598-9-227
   PubMed Web of Science ®Google Scholar
• Wan D, He S, Xie B, et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol. 2013;30:378.10.1007/s12032-012-0378-6
   PubMed Web of Science ®Google Scholar
• Nonaka R, Nishimura J, Kagawa Y, et al. Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep. 2014;32:2354–2358.
   PubMed Web of Science ®Google Scholar
• Gao Y, Feng Y, Shen JK. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma. Sci Rep. 2015;5:11365.10.1038/srep11365
   PubMed Web of Science ®Google Scholar
• Qu Y, Huang X, Li Z, et al. miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment. Am J Pathol. 2014;184:1541–1549.10.1016/j.ajpath.2014.01.017
   PubMed Web of Science ®Google Scholar
• Minna E, Romeo P, De Cecco L. miR-199a-3p displays tumor suppressor functions in papillary thyroid carcinoma. Oncotarget. 2014;5:2513–2528.10.18632/oncotarget
   PubMed Web of Science ®Google Scholar
• Wang CC, Friedman L, Kennedy GC, et al. Lanman RB.A large multicenter correlation study of thyroid nodule cytopathology and histopathology. Thyroid. 2011;21:243–251.10.1089/thy.2010.0243
   PubMed Web of Science ®Google Scholar
• Theoharis C, Roman S, Sosa JA. The molecular diagnosis and management of thyroid neoplasms. Curr Opin Oncol. 2012;24:35–41.10.1097/CCO.0b013e32834dcfca
   PubMed Web of Science ®Google Scholar
• Ferraz C, Eszlinger M, Paschke R. Current state and future perspective of molecular diagnosis of fine-needle aspiration biopsy of thyroid nodules. J Clin Endocrinol Metab. 2011;96:2016–2026.10.1210/jc.2010-2567
   PubMed Web of Science ®Google Scholar
• Kouniavsky G, Zeiger MA. The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology. J Surg Oncol. 2012;105:438–443.10.1002/jso.v105.5
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092–2098.10.1210/jc.2009-0247
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390–3397.10.1210/jc.2011-1469
   PubMed Web of Science ®Google Scholar
• Kim S-J, Lee KE, Myong JP. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 2012;36:310–317.10.1007/s00268-011-1383-1
   PubMed Web of Science ®Google Scholar
• Nam JK, Jung CK, Song BJ. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012;203:436–441.10.1016/j.amjsurg.2011.02.013
   PubMed Web of Science ®Google Scholar
• Cheng S, Serra S, Mercado M. A high-throughput proteomic approach provides distinct signatures for thyroid cancer behavior. Clin Cancer Res. 2011;17:2385–2394.10.1158/1078-0432.CCR-10-2837
   PubMed Web of Science ®Google Scholar
• Khoo MLC, Freeman JL, Witterick IJ. Underexpression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg. 2002;128:253–257.10.1001/archotol.128.3.253
   PubMedGoogle Scholar
• He H, Jazdzewski K, Li W, et al.The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005; 102:19075–19080.10.1073/pnas.0509603102
   PubMed Web of Science ®Google Scholar
• Visone R, Russo L, Pallante P, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14:791–798.10.1677/ERC-07-0129
   PubMed Web of Science ®Google Scholar
• Tetzlaff MT, Liu A, Xu X, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol. 2007;18:163–173.10.1007/s12022-007-0023-7
   PubMed Web of Science ®Google Scholar
• Pallante P, Visone R, Ferracin M, et al. MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer. 2006;13:497–508.10.1677/erc.1.01209
   PubMed Web of Science ®Google Scholar
• Ren X, Shen Y, Zheng S, et al. miR-21 predicts poor prognosis in patients with osteosarcoma. Br J Biomed Sci. 2016;73:158–162.10.1080/09674845.2016.1220710
   PubMed Web of Science ®Google Scholar
• Sun B, Liu X, Gao Y, et al. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. Br J Biomed Sci. 2016;73:152–157.10.1080/09674845.2016.1220706
   PubMed Web of Science ®Google Scholar
• Yip L, Kelly L, Shuai Y, et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol. 2011;18:2035–2041.10.1245/s10434-011-1733-0
   PubMed Web of Science ®Google Scholar
• Lee JC, Zhao JT, Clifton-Bligh RJ, et al. MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer. 2013;119:4358–4365.10.1002/cncr.28254
   PubMed Web of Science ®Google Scholar